Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2012

Open Access 01-12-2012 | Research

Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder

Authors: Qiong Zou, Li Xiong, Zhulin Yang, Fang Lv, Leping Yang, Xiongying Miao

Published in: World Journal of Surgical Oncology | Issue 1/2012

Login to get access

Abstract

Background

The objective of this study was to investigate CD9 and HMGA2 expression and its clinicopathological significance in benign and malignant lesion tissues of the gallbladder.

Methods

The resected specimens of 108 cases of gallbladder adenocarcinoma, 46 cases of adjacent tissue, 15 cases of polyps and 35 cases of chronic cholecystitis were made into conventional paraffin-embedded sections, using the method of EnVision immunohistochemistry to stain HMGA2 and CD9.

Results

HMGA2 expression of gallbladder adenocarcinoma was significantly higher than that of adenocarcinoma adjacent tissues (= 16.13, P <0.01), polyps (= 8.19, P <0.01) and chronic cholecystitis (= 21.41, P <0.01); but CD9 expression was the opposite (P <0.05 or P <0.01). The positive rate of HMGA2 expression from the cases that had well-differentiated adenocarcinoma, with the largest tumor diameter <2 cm, and without lymph node metastasis, and that did not invade the surrounding tissue was significantly lower than that of HMGA2 expression from the cases that had poorly differentiated adenocarcinoma, with the largest tumor diameter ≥2 cm, lymph node metastasis, and that invaded the surrounding tissues (P <0.05 or P <0.01). The positive rate of CD9 expression from the cases that had well-differentiated adenocarcinoma, with the largest tumor diameter <2 cm, and without lymph node metastasis, and that did not invade the surrounding tissue was significantly higher than that of CD9 expression from the cases that had poorly differentiated adenocarcinoma, with the largest tumor diameter ≥2 cm, lymph node metastasis, and which invaded the surrounding tissues (P <0.05 or P <0.01). The Kaplan-Meier survival analysis showed that after surgery, the survival period of HMGA2 expression-positive cases was significantly lower than that of HMGA2 expression- negative cases (P = 0.020), but the survival period of CD9 expression-positive cases was significantly higher than that of cases with CD9 expression-negative (P = 0.019). Cox multivariate regression analysis showed that the HMGA2 positive expression and/or CD9 negative expression was an important indicator reflecting the poor prognosis of gallbladder cancer.

Conclusion

The expression of HMGA2 and/or CD9 might be closely related to the carcinogenesis, clinical biological behaviors and prognosis of gallbladder adenocarcinoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jones RS: Carcinoma of the gallbladder. Surg Clin North Am. 1990, 70: 1419-1428.PubMed Jones RS: Carcinoma of the gallbladder. Surg Clin North Am. 1990, 70: 1419-1428.PubMed
2.
go back to reference Carriaga MT, Henson DE: Liver, gallbladder, extraHepatic bile ducts, and pancreas. Cancer. 1995, 75: 171-190. 10.1002/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO;2-2.CrossRefPubMed Carriaga MT, Henson DE: Liver, gallbladder, extraHepatic bile ducts, and pancreas. Cancer. 1995, 75: 171-190. 10.1002/1097-0142(19950101)75:1+<171::AID-CNCR2820751306>3.0.CO;2-2.CrossRefPubMed
3.
go back to reference Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M: Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res. 2008, 14: 2334-2340. 10.1158/1078-0432.CCR-07-4667.CrossRefPubMed Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M: Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res. 2008, 14: 2334-2340. 10.1158/1078-0432.CCR-07-4667.CrossRefPubMed
4.
go back to reference Hristov AC, Cope L, Reyes MD, Singh M, Iacobuzio-Donahue C, Maitra A, Resar LM: HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol. 2009, 22: 43-49. 10.1038/modpathol.2008.140.PubMedCentralCrossRefPubMed Hristov AC, Cope L, Reyes MD, Singh M, Iacobuzio-Donahue C, Maitra A, Resar LM: HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol. 2009, 22: 43-49. 10.1038/modpathol.2008.140.PubMedCentralCrossRefPubMed
5.
go back to reference Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, Vollmer E, Bullerdiek J: HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog. 2007, 46: 503-511. 10.1002/mc.20235.CrossRefPubMed Meyer B, Loeschke S, Schultze A, Weigel T, Sandkamp M, Goldmann T, Vollmer E, Bullerdiek J: HMGA2 overexpression in non-small cell lung cancer. Mol Carcinog. 2007, 46: 503-511. 10.1002/mc.20235.CrossRefPubMed
6.
go back to reference Chiappetta G, Ferraro A, Vuttariello E, Monaco M, Galdiero F, De Simone V, Califano D, Pallante P, Botti G, Pezzullo L, Pierantoni GM, Santoro M, Fusco A: HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer. 2008, 44: 1015-1021. 10.1016/j.ejca.2008.02.039.CrossRefPubMed Chiappetta G, Ferraro A, Vuttariello E, Monaco M, Galdiero F, De Simone V, Califano D, Pallante P, Botti G, Pezzullo L, Pierantoni GM, Santoro M, Fusco A: HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer. 2008, 44: 1015-1021. 10.1016/j.ejca.2008.02.039.CrossRefPubMed
7.
go back to reference Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K: Expression of mesenchyme-specific gene HMGA2 in squcell carcinomas of the oral cavity. Cancer Res. 2004, 64: 2024-2029. 10.1158/0008-5472.CAN-03-1855.CrossRefPubMed Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K: Expression of mesenchyme-specific gene HMGA2 in squcell carcinomas of the oral cavity. Cancer Res. 2004, 64: 2024-2029. 10.1158/0008-5472.CAN-03-1855.CrossRefPubMed
8.
go back to reference Malek A, Bakhidze E, Noske A: HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer. 2008, 123: 348-356. 10.1002/ijc.23491.CrossRefPubMed Malek A, Bakhidze E, Noske A: HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer. 2008, 123: 348-356. 10.1002/ijc.23491.CrossRefPubMed
9.
go back to reference Nakamoto T, Murayama Y, Oritani K, Boucheix C, Rubinstein E, Nishida M, Katsube F, Watabe K, Kiso S, Tsutsui S, Tamura S, Shinomura Y, Hayashi N: A novel therapeutic strategy with anti-CD9 antibody in gastric cancers. J Gastroenterol. 2009, 44: 889-896. 10.1007/s00535-009-0081-3.CrossRefPubMed Nakamoto T, Murayama Y, Oritani K, Boucheix C, Rubinstein E, Nishida M, Katsube F, Watabe K, Kiso S, Tsutsui S, Tamura S, Shinomura Y, Hayashi N: A novel therapeutic strategy with anti-CD9 antibody in gastric cancers. J Gastroenterol. 2009, 44: 889-896. 10.1007/s00535-009-0081-3.CrossRefPubMed
10.
go back to reference Zoller M: Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2009, 9: 40-55. 10.1038/nrc2543.CrossRefPubMed Zoller M: Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2009, 9: 40-55. 10.1038/nrc2543.CrossRefPubMed
11.
go back to reference Bari R, Zhang YH, Zhang F, Wang NX, Stipp CS, Zheng JJ, Zhang XA: Transmembrane interactions are needed for KALL/CD82-mediated suppression of cancer invasion and metastasis. Am J Pathol. 2009, 174: 647-660. 10.2353/ajpath.2009.080685.PubMedCentralCrossRefPubMed Bari R, Zhang YH, Zhang F, Wang NX, Stipp CS, Zheng JJ, Zhang XA: Transmembrane interactions are needed for KALL/CD82-mediated suppression of cancer invasion and metastasis. Am J Pathol. 2009, 174: 647-660. 10.2353/ajpath.2009.080685.PubMedCentralCrossRefPubMed
12.
go back to reference Gesierich S, Paret C, Hidebrand D, Weitz J, Zgraggen K, Schmitz-Winnenthal FH, Horejsi V, Yoshie O, Herlyn D, Ashman LK, Zöller M: Colocalization of the tetraspanins, Co-029 and CD151, with integrins in human pancreatic adenocarcinoma: Impact on cell motility. Clin Cancer Res. 2005, 11: 2840-2852. 10.1158/1078-0432.CCR-04-1935.CrossRefPubMed Gesierich S, Paret C, Hidebrand D, Weitz J, Zgraggen K, Schmitz-Winnenthal FH, Horejsi V, Yoshie O, Herlyn D, Ashman LK, Zöller M: Colocalization of the tetraspanins, Co-029 and CD151, with integrins in human pancreatic adenocarcinoma: Impact on cell motility. Clin Cancer Res. 2005, 11: 2840-2852. 10.1158/1078-0432.CCR-04-1935.CrossRefPubMed
13.
go back to reference Kanetaka K, Sakamoto M, Yamamoto Y, Yamasaki S, Lanza F, Kanematsu T, Hirohashi S: Overexpression of tetraspanin Co-029 in hepatocellular carcinoma. J Hepatol. 2001, 35: 637-642. 10.1016/S0168-8278(01)00183-0.CrossRefPubMed Kanetaka K, Sakamoto M, Yamamoto Y, Yamasaki S, Lanza F, Kanematsu T, Hirohashi S: Overexpression of tetraspanin Co-029 in hepatocellular carcinoma. J Hepatol. 2001, 35: 637-642. 10.1016/S0168-8278(01)00183-0.CrossRefPubMed
14.
go back to reference Mori M, Mimori K, Shiraishi T, Haraguchi M, Ueo H, Barnard GF, Akiyoshi T: Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin Cancer Res. 1998, 4: 1507-1510.PubMed Mori M, Mimori K, Shiraishi T, Haraguchi M, Ueo H, Barnard GF, Akiyoshi T: Motility related protein 1 (MRP1/CD9) expression in colon cancer. Clin Cancer Res. 1998, 4: 1507-1510.PubMed
15.
go back to reference Houle CD, Ding XY, Foley JF, Afshari CA, Barrett JC, Davis BJ: Loss of expression and altered localization of KAL1 and cd9 protein are associated with epithelial ovarian cancer progression. Gynecol Oncol. 2002, 86: 69-78. 10.1006/gyno.2002.6729.CrossRefPubMed Houle CD, Ding XY, Foley JF, Afshari CA, Barrett JC, Davis BJ: Loss of expression and altered localization of KAL1 and cd9 protein are associated with epithelial ovarian cancer progression. Gynecol Oncol. 2002, 86: 69-78. 10.1006/gyno.2002.6729.CrossRefPubMed
16.
go back to reference Dalie M, Chenguan B: Observe and judge the results with immunohistochemical positive marks. J Clin Exp Pathol. 2003, 19: 557-559. Dalie M, Chenguan B: Observe and judge the results with immunohistochemical positive marks. J Clin Exp Pathol. 2003, 19: 557-559.
17.
go back to reference Hock R, Furusawa T, Ueda T, Bustin M: HMG chromosomal proteins in development and disease. Trends Cell Biol. 2007, 17: 72-79. 10.1016/j.tcb.2006.12.001.PubMedCentralCrossRefPubMed Hock R, Furusawa T, Ueda T, Bustin M: HMG chromosomal proteins in development and disease. Trends Cell Biol. 2007, 17: 72-79. 10.1016/j.tcb.2006.12.001.PubMedCentralCrossRefPubMed
18.
go back to reference Wunderlich V, Bottger M: High-mobility-group proteins and cancer: an emerging link. J Cancer Res Clin Oncol. 1997, 123: 133-140.PubMed Wunderlich V, Bottger M: High-mobility-group proteins and cancer: an emerging link. J Cancer Res Clin Oncol. 1997, 123: 133-140.PubMed
19.
go back to reference Arihiro K, Kaneko M, Fujii S, Inai K: Loss of CD9 with expression of CD31 and VEGF in breast carcinoma, as predictive factors of lymph node metastasis. Breast Cancer. 1998, 5: 131-138. 10.1007/BF02966685.CrossRefPubMed Arihiro K, Kaneko M, Fujii S, Inai K: Loss of CD9 with expression of CD31 and VEGF in breast carcinoma, as predictive factors of lymph node metastasis. Breast Cancer. 1998, 5: 131-138. 10.1007/BF02966685.CrossRefPubMed
Metadata
Title
Expression levels of HMGA2 and CD9 and its clinicopathological significances in the benign and malignant lesions of the gallbladder
Authors
Qiong Zou
Li Xiong
Zhulin Yang
Fang Lv
Leping Yang
Xiongying Miao
Publication date
01-12-2012
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-10-92

Other articles of this Issue 1/2012

World Journal of Surgical Oncology 1/2012 Go to the issue